https://www.selleckchem.com/products/fhd-609.html
sk. The predictive value was validated in an independent set of 197 patients with iMCD from The International Castleman Disease Consortium. The proposed novel model is valuable for predicting clinical outcome and selecting optimal therapies using clinical parameters. 40 years, plasmacytic variant subtype, hepatomegaly and/or splenomegaly, hemoglobin less then 80 g/L, and pleural effusion, and stratified patients into three risk categories low risk, intermediate risk, and high risk. The predictive value was validated in an independent se
Like
Comment
Share
